medigraphic.com

2019, Number 3

<< Back Next >>

Anales de Radiología México 2019; 18 (3)

The importance of diagnostic imaging on hepatocellular carcinoma. Actual role of PET-CT

Zamora-Soberón CA, Angulo-Salazar D, Herrera-Zarza MC, Criales-Cortés JL

Language: Spanish
References: 35
Page: 177-186
PDF size: 2736.26 Kb.


ABSTRACT

Hepatocellular carcinoma (HCC) is currently the sixth most frequent neoplasm worldwide and the third cause of death related to cancer. The survival rate depends among other things on tumor burden and size, in addition to an opportune treatment. Actually, ultrasound is the main screening tool in patients with cirrhotic liver with risk of developing HCC. Sectional imaging such as tomography and magnetic resonance allows diagnostic with the presence of intense arterial enhancement, lavage in venoportal phase and sometimes a higher density capsule in late sequences. Currently, positron emission tomography fuses the metabolic analysis with the sectional image, allowing an accurate staging in patients with HCC and monitor the response to treatment. Radiotracers like 18-fluorodeoxyglucose and 11-carbon are useful prognostic tools and provide indirect information on tumor differentiation. The future development of diagnostic technologies and the use of new radiotracers opens up new possibilities in the diagnosis and monitoring of patients with HCC.


REFERENCES

  1. Shariff MI, Cox IJ, Gomaa AI, Khan SA, Gedroyc W, Taylor-Robinson SD. Hepatocellular carcinoma:current trends in worldwide epidemiology, risk factors, diagnosis and therapeutics. Expert Rev Gastroenterol Hepatol. 2009;3:353-67.

  2. Ghouri YA, Mian I, Rowe JH. Review of hepatocellular carcinoma:Epidemiology, etiology, and carcinogenesis. J. Carcinog. 2017;16:1.

  3. El-Serag HB. Hepatocellular Carcinoma. N. Engl. J. Med. 2011;365:1118-27.

  4. Parkin DM. The global health burden of infection-associated cancers in the year 2002. Int J Cancer. 2006;118:3030-44.

  5. Zhang DY, Friedman SL. Fibrosis-dependent mechanisms of hepatocarcinogenesis. Hepatology. 2012;56:769-75.

  6. Livraghi T, Meloni F, Di Stasi M, Rolle E, Solbiati L, Tinelli C, Rossi S. Sustained complete response and complications rates after radiofrequency ablation of very early hepatocellular carcinoma in cirrhosis:Is resection still the treatment of choice?Hepatology. 2007;47:82-9.

  7. Roayaie S, Blume IN, Thung SN, Guido M, Fiel MI, Hiotis S, et al. A system of classifying microvascular invasion to predict outcome after resection in patients with hepatocellular carcinoma. Gastroenterology. 2009;137:850-5.

  8. Roayaie S, Obeidat K, Sposito C, Mariani L, Bhoori S, Pellegrinelli A, et al. Resection of hepatocellular cancer ≤2 cm:results from two Western centers. Hepatology. 2013;57:1426-35.

  9. Daniele B, Bencivenga A, Megna AS,Tinessa, V. ?-fetoprotein and ultrasonography screening for hepatocellular carcinoma. Gastroenterology. 2004;127:S108-12.

  10. Ahn DG, Kim HJ, Kang H, Lee HW, Bae SH, Lee JH, et al. Feasibility of ?-fetoprotein as a diagnostic tool for hepatocellular carcinoma in Korea. Korean J Intern Med. 2016;31:46-53.

  11. Tzartzeva K, Obi J, Rich NE, Parikh ND, Marrero JA, Yopp A, et al. Surveillance Imaging and Alpha Fetoprotein for Early Detection of Hepatocellular Carcinoma in Patients With Cirrhosis:A Meta-analysis. Gastroenterology. 2018;154:1706-18.e1.

  12. Sato T, Kondo F, Ebara M, Sugiura N, Okabe S, Sunaga M, et al. Natural history of large regenerative nodules and dysplastic nodules in liver cirrhosis:28-year follow-up study. Hepatol Int. 2015;9:330-6.

  13. Cassinotto C, AubéC, Dohan A. Diagnosis of hepatocellular carcinoma:An update on international guidelines. Diagn. Interv. Imaging. 2017;98:379-91.

  14. Röcken C, Carl-McGrath S. Pathology and Pathogenesis of Hepatocellular Carcinoma. Dig Dis. 2001;19:269-78.

  15. Roskams T, Kojiro M. Pathology of Early Hepatocellular Carcinoma:Conventional and Molecular Diagnosis. Semin Liver Dis. 2010;30:017-25.

  16. European Association For The Study Of The Liver &European Organisation For Research And Treatment Of Cancer. EASL–EORTC Clinical Practice Guidelines:Management of hepatocellular carcinoma. J. Hepatol. 2012:56:908-43.

  17. Heimbach JK, Kulik LM, Finn RS, Sirlin CB, Abecassis MM, Roberts LR, et al. AASLD Guidelines for the Treatment of Hepatocellular Carcinoma. Hepatology. 2018;67(1):358-80.

  18. Ignee A, Weiper D, Schuessler G, Teuber G, Faust D, Dietrich CF. Sonographic Characterisation of Hepatocellular Carcinoma at Time of Diagnosis. Z Gastroenterol. 2005;43:28.94.

  19. Chen RC, Chen WT, Liao LY, Cheng NY, Wang CK, Tu HY, et al. Intravenous contrast-enhanced doppler sonography and intra-arterial carbon dioxide- enhanced sonography in the assessment of hepatocellular carcinoma vascularity before and after treatment. Acta Radiol. 2002;43:411-4.

  20. Fiore F, Vallone P, Ricchi P, Tambaro R, Daniele B, Sandomenico F, et al. Levovist-enhanced Doppler Sonography Versus Spiral Computed Tomography to Evaluate Response to Percutaneous Ethanol Injection in Hepatocellular Carcinoma. J Clin Gastroenterol. 2000;31:164-68.

  21. LI-RADS ® v2017 CEUS Core CEUS Diagnostic Table.

  22. Matos AP, Velloni F, Ramalho M, AlObaidy M, Rajapaksha A, Semelka RC. Focal liver lesions:Practical magnetic resonance imaging approach. World J Hepatol. 2015;7:1987-2008.

  23. Khosa F, Khan AN, Eisenberg RL. Hypervascular liver lesions on MRI. Am J Roentgenol. 2011;197(2):W204-20.

  24. D'Ippolito G, Fernando Appezzato L, Caivano RAC, de Abreu L Junior, Borri ML, Galvão Filho MM. Apresentações incomuns do hepatocarcinoma:ensaio iconográfico. Radiol Bras. 2006;39:137-43.

  25. Elsayes KM, Hooker JC, Agrons MM, Kielar AZ, Tang A, Fowler KJ, et al. 2017 Version of LI-RADS for CT and MR Imaging:An Update. Radiographics. 2017;37:1994-2017.

  26. Cossio-Torrico PE, Ramírez-Carmonab CR, Stoopen-Romettic M, Perochena-González A, Sosa-Lozanod LA, E. Kimura-Hayamac E, et al. Resonancia magnética con ácido gadoxético —contraste hepatoespecífico—para la evaluación de lesiones focales. Rev Gastroenterol México. 2015;80:267-75.

  27. Van Beers BE, Pastor CM, Hussain HK. Primovist, Eovist:What to expect?. J. Hepatol. 2012;57:421-9.

  28. Motosugi U, Ichikawa T, Tominaga L, Sou H, Sano K, Ichikawa S, et al. Delay before the hepatocyte phase of Gd-EOB-DTPA-enhanced MR imaging:Is it possible to shorten the examination time?. Eur Radiol. 2009;19:2623-9.

  29. Ho CL, Yu SCH, Yeung DWC. 11C-acetate PET imaging in hepatocellular carcinoma and other liver masses. J Nucl Med. 2003;44:213-21.

  30. Larsson P, Arvidsson D, Björnstedt M, Isaksson B, Jersenius U, Motarjemi H. Adding 11C-acetate to 18F-FDG at PET Examination Has an Incremental Value in the Diagnosis of Hepatocellular Carcinoma. Mol Imaging Radionucl Ther. 2012;21:6-12.

  31. Park JW, Kim JH, Kim SK, Kang KW, Park KW, Choi JI, et al. A Prospective Evaluation of 18F-FDG and 11C-Acetate PET/CT for Detection of Primary and Metastatic Hepatocellular Carcinoma. J Nucl Med. 2008;49:1912-23.

  32. Ho CL, Chen S, Yeung, DW, Cheng TK. Dual-Tracer PET/CT Imaging in Evaluation of Metastatic Hepatocellular Carcinoma. J Nucl Med. 2007;48:902-9.

  33. Huo L, Dang Y, Lim F. Application of dual phase imaging of 11C-acetate positron emission tomography on differential diagnosis of small hepatic lesions. Mol Imaging Biol. 2015;17.

  34. Mazzaferro V, Regalia E, Doci R, Andreola S, Pulvirenti A, Bozzetti F, et al. Liver Transplantation for the Treatment of Small Hepatocellular Carcinomas in Patients with Cirrhosis. N Engl J Med. 1996;334:693-700.

  35. Jianyong L, Lunan Y, Wentao W, Yong Z, Bo L, Tianfu W, et al. Barcelona Clinic Liver Cancer Stage B Hepatocellular Carcinoma. Medicine (Baltimore). 2014;93:e180.




2020     |     www.medigraphic.com